ATNM
Actinium Pharmaceuticals Inc
AMEX: ATNM · HEALTHCARE · BIOTECHNOLOGY
$1.39
+6.11% today
Updated 2026-09-11
Market cap
$44.02M
P/E ratio
4.00
P/S ratio
1.25x
EPS (TTM)
$0.35
Dividend yield
—
52W range
$1 – $2
Volume
0.1M
Actinium Pharmaceuticals Inc (ATNM) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$1.39
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 4.00x (capped 25x) · Margin: 32.20%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.